PE20121478A1 - Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada - Google Patents
Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejoradaInfo
- Publication number
- PE20121478A1 PE20121478A1 PE2012000342A PE2012000342A PE20121478A1 PE 20121478 A1 PE20121478 A1 PE 20121478A1 PE 2012000342 A PE2012000342 A PE 2012000342A PE 2012000342 A PE2012000342 A PE 2012000342A PE 20121478 A1 PE20121478 A1 PE 20121478A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- teriflunomide
- cellulose
- trifluoromethylphenil
- hydroxibut
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 title abstract 2
- 229960000331 teriflunomide Drugs 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 229920001353 Dextrin Polymers 0.000 abstract 2
- 239000004375 Dextrin Substances 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 235000019425 dextrin Nutrition 0.000 abstract 2
- 229930091371 Fructose Natural products 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 abstract 1
- 239000008116 calcium stearate Substances 0.000 abstract 1
- 235000013539 calcium stearate Nutrition 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920003124 powdered cellulose Polymers 0.000 abstract 1
- 235000019814 powdered cellulose Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000015424 sodium Nutrition 0.000 abstract 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 abstract 1
- 235000010234 sodium benzoate Nutrition 0.000 abstract 1
- 239000004299 sodium benzoate Substances 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 235000012222 talc Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE: (A) DE 1% A 30% PESO/PESO DE TERIFLUNOMIDA; (B) DE 5% A 20% PESO/PESO DE UN DISGREGRANTE TAL COMO: CARBOXIMETILCELULOSA, CELULOSA MICROCRISTALINA, CELULOSA EN POLVO, CROSCARMELOSA SODIO, ENTRE OTROS; (C) DE 0% A 40% PESO/PESO DE UN LIGANTE TAL COMO: GOMA ARABIGA, CARBOXIMETILCELULOSA, DEXTRINA, GELATINA, GOMA DE GUAR, ENTRE OTROS; (D) DE 0.1% A 2% PESO/PESO DE UN LUBRICANTE TAL COMO: ESTEARATO DE CALCIO, BENZOATO DE SODIO, LAURILSULFATO DE SODIO, ACIDO ESTEARICO, TALCO, ENTRE OTROS; (E) EL RESTO DEL PORCENTAJE COMPRENDE DILUYENTES TALES COMO CELULOSA, ACETATO DE CELULOSA, DEXTRINA, DEXTROSA, FRUCTUOSA, ENTRE OTROS; CON LA CONDICION DE QUE LA COMPOSICION NO CONTENGA DIOXIDO DE SILICIO COLOIDAL. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA SEPSIS, ALERGIA, ARTRITIS REUMATOIDE, LEUCEMIA, ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290716 | 2009-09-18 | ||
| US36338210P | 2010-07-12 | 2010-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121478A1 true PE20121478A1 (es) | 2012-11-12 |
Family
ID=41510564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000342A PE20121478A1 (es) | 2009-09-18 | 2010-09-14 | Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada |
| PE2015002059A PE20152031A1 (es) | 2009-09-18 | 2010-09-14 | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002059A PE20152031A1 (es) | 2009-09-18 | 2010-09-14 | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada |
Country Status (40)
| Country | Link |
|---|---|
| US (5) | US20120172427A1 (es) |
| EP (1) | EP2477611B1 (es) |
| JP (1) | JP2013505213A (es) |
| KR (1) | KR101547880B1 (es) |
| CN (4) | CN104739821B (es) |
| AR (1) | AR078383A1 (es) |
| AU (2) | AU2010297357B2 (es) |
| BR (1) | BR112012006184B1 (es) |
| CA (1) | CA2772275A1 (es) |
| CL (1) | CL2015000047A1 (es) |
| CO (1) | CO6511244A2 (es) |
| CR (2) | CR20170078A (es) |
| CY (1) | CY1119364T1 (es) |
| DK (1) | DK2477611T3 (es) |
| DO (1) | DOP2012000070A (es) |
| ES (1) | ES2625731T3 (es) |
| GT (1) | GT201200075A (es) |
| HK (2) | HK1206244A1 (es) |
| HN (1) | HN2012000576A (es) |
| HR (1) | HRP20170904T1 (es) |
| HU (1) | HUE032963T2 (es) |
| IL (3) | IL218492A (es) |
| JO (1) | JO3327B1 (es) |
| LT (1) | LT2477611T (es) |
| MA (1) | MA33585B1 (es) |
| ME (1) | ME02765B (es) |
| MX (1) | MX336663B (es) |
| MY (1) | MY155613A (es) |
| NZ (2) | NZ617025A (es) |
| PE (2) | PE20121478A1 (es) |
| PL (1) | PL2477611T3 (es) |
| PT (1) | PT2477611T (es) |
| RS (1) | RS56074B1 (es) |
| RU (2) | RU2012115459A (es) |
| SI (1) | SI2477611T1 (es) |
| TN (1) | TN2012000061A1 (es) |
| TW (2) | TWI522130B (es) |
| UA (2) | UA107582C2 (es) |
| UY (1) | UY32889A (es) |
| WO (1) | WO2011032929A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2477611T3 (en) * | 2009-09-18 | 2017-07-10 | Sanofi Sa | (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY |
| RU2493845C1 (ru) * | 2012-06-07 | 2013-09-27 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Композиция для лечения рассеянного склероза (варианты) |
| KR20160079123A (ko) * | 2013-11-22 | 2016-07-05 | 젠자임 코포레이션 | 신경변성 질병을 치료하기 위한 신규한 방법 |
| CN103656657A (zh) * | 2013-12-18 | 2014-03-26 | 北京科源创欣科技有限公司 | 特立氟胺药物组合物及制备方法 |
| SI3122358T1 (sl) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
| CA2996632C (en) | 2015-09-01 | 2023-10-17 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| WO2017037645A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical formulations of teriflunomide |
| WO2017056104A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Limited | Stable pharmaceutical compositions of teriflunomide |
| WO2017125841A1 (en) * | 2016-01-20 | 2017-07-27 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of teriflunomide |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| DK3999038T3 (da) * | 2019-07-17 | 2024-03-18 | Cytokinetics Inc | Orale formuleringer af en kardial sarcomer-inhibitor |
| WO2022085015A1 (en) * | 2020-10-24 | 2022-04-28 | V-Ensure Pharma Technologies Private Limited | A solid oral composition of teriflunomide |
| GR1010137B (el) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης |
| TR202022336A2 (tr) * | 2020-12-30 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising teriflunomide |
| EP4382097A1 (en) | 2022-11-25 | 2024-06-12 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet comprising teriflunomide |
| WO2024112298A1 (en) * | 2022-11-25 | 2024-05-30 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising teriflunomide |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3852294A (en) * | 1968-08-27 | 1974-12-03 | Merck Patent Gmbh | Bis-quaternary pyridinium salts |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US6133301A (en) | 1991-08-22 | 2000-10-17 | Aventis Pharma Deutschland Gmbh | Pharmaceuticals for the treatment of rejection reactions in organ transplantations |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| ES2148561T3 (es) | 1994-10-17 | 2000-10-16 | Aventis Pharma Ltd | Prevencion y curacion de enfermedades alergicas de tipo i. |
| DK0987256T3 (da) | 1997-08-08 | 2002-02-11 | Aventis Pharma Gmbh | Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2001060363A1 (en) | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| SI1381356T1 (sl) | 2001-04-05 | 2008-12-31 | Aventis Pharma Inc | Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze |
| US20050158371A1 (en) | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| AU2004270174B2 (en) * | 2003-08-29 | 2010-05-20 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| US20050220874A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist |
| US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
| EP1804782A1 (en) * | 2004-10-19 | 2007-07-11 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| TWI275029B (en) * | 2005-11-18 | 2007-03-01 | Hon Hai Prec Ind Co Ltd | An embedded system and method for processing data thereof |
| CN101360493A (zh) | 2006-01-24 | 2009-02-04 | 特瓦制药工业有限公司 | 左乙拉西坦制剂和制备方法 |
| DE102006017896A1 (de) * | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| EP1990048A3 (en) | 2007-05-08 | 2009-05-06 | Ulrike Wiebelitz | Therapy of benign prostatic hyperplasia (bph) |
| DK2477611T3 (en) * | 2009-09-18 | 2017-07-10 | Sanofi Sa | (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY |
| EP2762135A1 (en) * | 2013-02-04 | 2014-08-06 | Sanofi | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
-
2010
- 2010-09-14 DK DK10752585.9T patent/DK2477611T3/en active
- 2010-09-14 NZ NZ617025A patent/NZ617025A/en unknown
- 2010-09-14 CR CR20170078A patent/CR20170078A/es unknown
- 2010-09-14 CA CA2772275A patent/CA2772275A1/en not_active Abandoned
- 2010-09-14 MY MYPI2012000646A patent/MY155613A/en unknown
- 2010-09-14 PT PT107525859T patent/PT2477611T/pt unknown
- 2010-09-14 EP EP10752585.9A patent/EP2477611B1/en not_active Revoked
- 2010-09-14 CN CN201510052299.XA patent/CN104739821B/zh not_active Ceased
- 2010-09-14 MX MX2012003122A patent/MX336663B/es unknown
- 2010-09-14 AU AU2010297357A patent/AU2010297357B2/en active Active
- 2010-09-14 SI SI201031476A patent/SI2477611T1/sl unknown
- 2010-09-14 UA UAA201204827A patent/UA107582C2/ru unknown
- 2010-09-14 RU RU2012115459/15A patent/RU2012115459A/ru unknown
- 2010-09-14 UA UAA201409985A patent/UA115979C2/uk unknown
- 2010-09-14 JP JP2012529234A patent/JP2013505213A/ja not_active Abandoned
- 2010-09-14 CN CN201510052347.5A patent/CN104666272A/zh active Pending
- 2010-09-14 PE PE2012000342A patent/PE20121478A1/es not_active Application Discontinuation
- 2010-09-14 NZ NZ598744A patent/NZ598744A/xx unknown
- 2010-09-14 RU RU2015151938A patent/RU2681079C2/ru active
- 2010-09-14 PL PL10752585T patent/PL2477611T3/pl unknown
- 2010-09-14 RS RS20170589A patent/RS56074B1/sr unknown
- 2010-09-14 ME MEP-2017-134A patent/ME02765B/me unknown
- 2010-09-14 CN CN201080041529.8A patent/CN102596184B/zh active Active
- 2010-09-14 BR BR112012006184-4A patent/BR112012006184B1/pt active IP Right Grant
- 2010-09-14 CN CN201510052300.9A patent/CN104666238B/zh not_active Ceased
- 2010-09-14 KR KR1020127006940A patent/KR101547880B1/ko active IP Right Grant
- 2010-09-14 PE PE2015002059A patent/PE20152031A1/es active IP Right Grant
- 2010-09-14 US US13/395,586 patent/US20120172427A1/en not_active Abandoned
- 2010-09-14 HU HUE10752585A patent/HUE032963T2/en unknown
- 2010-09-14 ES ES10752585.9T patent/ES2625731T3/es active Active
- 2010-09-14 LT LTEP10752585.9T patent/LT2477611T/lt unknown
- 2010-09-14 WO PCT/EP2010/063439 patent/WO2011032929A1/en active Application Filing
- 2010-09-16 TW TW103142089A patent/TWI522130B/zh active
- 2010-09-16 JO JOP/2010/0317A patent/JO3327B1/ar active
- 2010-09-16 TW TW99131364A patent/TWI468190B/zh active
- 2010-09-16 UY UY0001032889A patent/UY32889A/es not_active Application Discontinuation
- 2010-09-16 AR ARP100103381A patent/AR078383A1/es not_active Application Discontinuation
-
2012
- 2012-02-10 TN TNP2012000061A patent/TN2012000061A1/en unknown
- 2012-03-05 IL IL218492A patent/IL218492A/en active IP Right Grant
- 2012-03-12 CR CR20120116A patent/CR20120116A/es unknown
- 2012-03-13 MA MA34687A patent/MA33585B1/fr unknown
- 2012-03-15 CO CO12045392A patent/CO6511244A2/es active IP Right Grant
- 2012-03-16 US US13/422,494 patent/US8802735B2/en active Active
- 2012-03-16 DO DO2012000070A patent/DOP2012000070A/es unknown
- 2012-03-16 HN HN2012000576A patent/HN2012000576A/es unknown
- 2012-03-16 GT GT201200075A patent/GT201200075A/es unknown
-
2013
- 2013-11-18 AU AU2013257516A patent/AU2013257516B2/en active Active
-
2014
- 2014-04-30 US US14/265,433 patent/US20140235888A1/en not_active Abandoned
-
2015
- 2015-01-08 CL CL2015000047A patent/CL2015000047A1/es unknown
- 2015-07-16 HK HK15106785.9A patent/HK1206244A1/xx unknown
- 2015-07-16 HK HK15106786.8A patent/HK1206245A1/xx unknown
-
2016
- 2016-03-28 IL IL244809A patent/IL244809B/en active IP Right Grant
- 2016-10-11 US US15/290,677 patent/US20170247319A1/en not_active Abandoned
-
2017
- 2017-06-13 HR HRP20170904TT patent/HRP20170904T1/hr unknown
- 2017-07-04 CY CY20171100710T patent/CY1119364T1/el unknown
-
2018
- 2018-08-20 US US15/999,565 patent/US20190241505A1/en not_active Abandoned
-
2019
- 2019-02-19 IL IL26491219A patent/IL264912B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121478A1 (es) | Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada | |
| ES2563323T3 (es) | Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| EA201170911A1 (ru) | Синтез стирилпиридинов, меченных радиоактивным изотопомf, из предшественников тозилата и их стабильные фармацевтические композиции | |
| MX2015018048A (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| PH12017501911A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EA201190092A1 (ru) | Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) | |
| EA201490456A1 (ru) | Тернесит в качестве присадки к портландцементу | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| UA116809C2 (uk) | Застосування агрохімічних сумішей для збільшення життєздатності рослини | |
| MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
| MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| MA34055B1 (fr) | Chlorhydrate d'agomelatine hydrate et sa preparation | |
| MY163070A (en) | Process to produce valerolactone from levulinic acid | |
| EA201490152A1 (ru) | Антагонисты trpm8 и их применение при лечении | |
| PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| SG179031A1 (en) | Hsl inhibitors useful in the treatment of diabetes | |
| PH12015502684B1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
| AR087168A1 (es) | Compuesto derivado de pirimidina sulfonamida | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| UA101654C2 (uk) | Матриксна фармацевтична композиція на основі гідросульфату (2-гідроксіетоксі)аміду 6-(4-бром-2-хлорфеніламіно)-7-фтор-3-метил-3н-бензоімідазол-5-карбонової кислоти | |
| MX2020002196A (es) | Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |